Answers are grounded in this paper and cite their sources.
This article presents changes to clinical guidelines for the treatment of metastatic colon cancer in 2024. The new provisions in the clinical guidelines are complemented by a brief overview of the research results that underlie them. The changes considered concern not only systemic antitumor treatment, but also surgery and molecular genetic diagnostics. The differences between the recommendations of RUSSCO and the Ministry of Health of Russia are given. The introduction of information to determine the clinical benefit of expensive therapeutic options in relation to the use of the ESMO-MCBS and RUSSCO-MCBS scales is discussed.Aim. Bringing information to a wide range of readers on planned changes in clinical guidelines.
No takes yet. Share an insight, caveat, or question.
Fedyanin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: